| Literature DB >> 26633009 |
Ketan S Patil1, Indranil Basak1, Ramavati Pal1, Hsin-Pin Ho2, Guido Alves3, Emmanuel J Chang2, Jan Petter Larsen3, Simon Geir Møller1,3.
Abstract
MicroRNAs are key regulators associated with numerous diseases. In HEK293 cells, miR-153-3p and miR-205-5p down-regulate alpha-synuclein (SNCA) and Leucine-rich repeat kinase 2 (LRRK2), two key proteins involved in Parkinson's disease (PD). We have used two-dimensional gel electrophoresis (2D-PAGE) coupled to mass spectrometry (MS) to identify a spectrum of miR-153-3p and miR-205-5p targets in neuronal SH-SY5Y cells. We overexpressed and inhibited both microRNAs in SH-SY5Y cells and through comparative proteomics profiling we quantified ~240 protein spots from each analysis. Combined, thirty-three protein spots were identified showing significant (p-value < 0.05) changes in abundance. Modulation of miR-153-3p resulted in seven up-regulated proteins and eight down-regulated proteins. miR-205 modulation resulted in twelve up-regulated proteins and six down-regulated proteins. Several of the proteins are associated with neuronal processes, including peroxiredoxin-2 and -4, cofilin-1, prefoldin 2, alpha-enolase, human nucleoside diphosphate kinase B (Nm23) and 14-3-3 protein epsilon. Many of the differentially expressed proteins are involved in diverse pathways including metabolism, neurotrophin signaling, actin cytoskeletal regulation, HIF-1 signaling and the proteasome indicating that miR-153-3p and miR-205-5p are involved in the regulation of a wide variety of biological processes in neuroblastoma cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26633009 PMCID: PMC4669106 DOI: 10.1371/journal.pone.0143969
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Overexpression and inhibition of miR-153-3p and miR-205-5p and their effect on cell viability in SH-SY5Y cells.
(A-B) Semi-quantitative RT-PCR analysis showing miR-153-3p expression levels in response to mimic (A) and antagomir (B) transfections. miR-205-5p expression levels in response to mimic (A) and antagomir (B) transfections. (C) qRT-PCR analysis confirming the antagomir mediated inhibition of miR-153-3p (C) and miR-205-5p. (D) Cell viability assay. U6 was used as loading controls for qRT-PCR. Error bars indicate SEM (n = 3); *, p < 0.05, ***; p < 0.001.
Fig 2Comparative proteomic profiling in SH-SY5Y.
Two-dimensional gels of control mimic, miR-153-3p mimic, control antagomir and miR-153-3p antagomir transfected cells. n = 3 for all experiments. Numbers (1–15) represent differentially expressed protein spots identified by MS, reported in Table 1.
Fig 3Comparative proteomic profiling in SH-SY5Y.
Two-dimensional gels of control mimic, miR-205-5p mimic, control antagomir and miR-205-5p antagomir transfected cells. n = 3 for all experiments. Numbers (16–33) represent differentially expressed protein spots identified by MS, reported in Table 1.
List of differentially regulated proteins in SH-SY5Y cells in response to mimics and antagomirs of miR-153-3p and miR-205-5p.
| Spot No. | UniProt Accession | Description | Sequence coverage | Fold change | Significance p-value |
|---|---|---|---|---|---|
|
| |||||
| 1 | P32119 | Peroxiredoxin-2 | 27 | 1.66 ± 0.13 | 0.03 |
| 2 | P11177 | Pyruvate dehydrogenase beta subunit | 12 | 2.26 ± 0.19 | 0.04 |
| 3 | P09429 | High mobility group protein B1 (HMGB-1) | 26 | 1.64 ± 0.11 | 0.02 |
| 4 | P25786 | Proteasome subunit alpha type-1 isoform 2 | 20 | 1.49 ± 0.09 | 0.03 |
| P31948 | Stress-induced-phosphoprotein 1 | 13 | |||
|
| |||||
| 5 | Q8IW75 | Serpin A12 precursor | 1 | 1.44 ± 0.04 | 0.04 |
| 6 | P38646 | Heat shock 70kDa protein 9 (mortalin) | 24 | 1.84 ± 0.22 | 0.003 |
| 7 | Q9UHV9 | Prefoldin subunit 2 | 16 | 2.34 ± 0.25 | 0.04 |
|
| |||||
| 8 | P05388 | 60S acidic ribosomal protein P0 | 35 | 2.24 ± 0.13 | 0.05 |
| 9 | Q13162 | Peroxiredoxin-4 precursor | 30 | 2.03 ± 0.43 | 0.05 |
| Q14CN2 | Ca2+-activated chloride channel protein 2 | 3 | |||
| 10 | P22392 | Human Nucleoside Diphosphate Kinase B (Nm23) | 36 | 1.61 ± 0.14 | 0.008 |
|
| |||||
| 11 | P06733 | Alpha-enolase | 13 | 3.18 ± 0.09 | 0.01 |
| 12 | P13929 | Beta-enolase | 22 | 1.84 ± 0.13 | 0.03 |
| 13 | Q9UBR2 | Cathepsin Z precursor | 6 | 2.65 ± 0.16 | 0.01 |
| 14 | P23528 | Cofilin-1 | 53 | 2.11 ± 0.20 | 0.004 |
| 15 | P68104 | Elongation factor 1-alpha 1 | 10 | 2.55 ± 0.64 | 0.01 |
| P62258 | 14-3-3 protein epsilon | 24 | |||
|
| |||||
| 16 | Q13765 | Nascent-polypeptide-associated complex alpha (HSD48) | 25 | 1.80 ± 0.28 | 0.05 |
| 17 | P63241 | Eukaryotic translation initiation factor 5A-1 isoform B | 22 | 2.28 ± 0.27 | 0.05 |
| 18 | P23528 | Cofilin-1 | 43 | 2.11 ± 0.77 | 0.009 |
| 19 | P32119 | Peroxiredoxin-2 | 21 | 1.99 ± 0.03 | 0.05 |
| 20 | P04083 | Annexin A1 | 7 | 2.08 ± 0.16 | 0.04 |
| 21 | P25786 | Proteasome subunit alpha type-1 isoform 2 | 9 | 1.61 ± 0.16 | 0.001 |
| 22 | Q13126 | Methylthioadenosine phosphorylase | 16 | 1.80 ± 0.24 | 0.04 |
| 23 | Q13347 | Eukaryotic translation initiation factor 3 subunit I | 13 | 1.55 ± 0.03 | 0.04 |
| 24 | P62333 | Proteasome subunit p42 | 3 | 1.90 ± 0.09 | 0.04 |
|
| |||||
| 25 | P50213 | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial precursor | 23 | 2.02 ± 0.24 | 0.007 |
| P04406 | Glyceraldehyde-3-phosphate dehydrogenase | 4 | |||
| 26 | Q8IW75 | Serpin A12 precursor | 1 | 2.38 ± 0.50 | 0.03 |
|
| |||||
| 27 | Q13148 | TAR DNA-binding protein 43 | 7 | 2.03 ± 0.09 | 0.01 |
| 28 | Q07955 | Serine/arginine-rich splicing factor 1 isoform 1 | 53 | 2.24 ± 0.58 | 0.04 |
| 29 | Q13162 | Peroxiredoxin-4 precursor | 33 | 1.66 ± 0.09 | 0.04 |
|
| |||||
| 30 | P09382 | Human Galectin-1 | 52 | 1.80 ± 0.22 | 0.03 |
| 31 | P22392 | Human Nucleoside Diphosphate Kinase B (Nm23) | 24 | 1.55 ± 0.00 | 0.03 |
| 32 | P23528 | Cofilin-1 | 34 | 2.11 ± 0.30 | 0.02 |
| 33 | Q13765 | Nascent-polypeptide-associated complex alpha (HSD48) | 25 | 1.69 ± 0.00 | 0.05 |
| Q01105 | Protein SET | 5 | |||
–Single peptides identified from individual protein spots in two (), three () or seven () independent MALDI-MS detections. All the protein spots were picked and analyzed from at-least two independent experiments. Fold change ± error are calculated with respect to control mimic and control inhibitor by ImageMaster 2D platinum 7 (GE) software. The significance was calculated using two-tailed t-test.
Fig 4Protein association network showing interconnecting relationships between miR-153-3p and miR-205-5p target proteins through key regulatory pathways.
YWHAE: 14-3-3 epsilon protein; ENO1: Alpha-enolase; ENO3: beta-enolase; IDH3A: Isocitrate dehydrogenase [NAD] subunit alpha; PDHB: Pyruvate dehydrogenase complex beta subunit; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
Fig 5Verification of differentially expressed proteins by Western blot analysis and ROS changes in response to miR-153-3p and miR-205-5p.
Western blot analysis showing effect of miR-153-3p mimic on (A) PRDX2 and HMGB1 levels (B) effect of miR-153-3p antagomir on Cfl1 levels, (C) effect of miR-205-5p mimic on PRDX2, NACA and Cfl1 levels, (D) effect of miR-205-5p antagomir on NACA and Cfl1 levels. (E) Quantification of ROS levels in SH-SY5Y cells by modulating miR-153-3p and miR-205-5p levels. Percentage change in DCF fluorescence compared to control is shown. (F) Proposed pathway for ROS reduction due to miR-153-3p and miR-205-5p by regulation of PRDX2. Error bars indicate SEM (n = 3); *, p < 0.05; **, p < 0.01, ***; p < 0.001.